LOXL2, catalyzes the cross-linking of collagen and elastin fibers, contributing to tissue stiffening and progression of fibrosis. By blocking LOXL2, simtuzumab aimed to slow or reverse fibrotic remodeling, though clinical trials in IPF and NASH did not demonstrate significant efficacy, leading to discontinuation of development.